Lyell Immunopharma Inc
Lyell Immunopharma Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. It develops BioPulse treatment which modulates the expression of tumor antigens to amplify cellular immunotherapy. The company offers B-chimeric antigen receptor (CAR) to stimulate infiltration of T cells into cancer cells. Its cytokine treatments include OncoPuls, which aims at generating self-amplifying CAR populations expressing a single target antigen; and UniPuls, which has the potential to express multiple antigens and can be used with conventional chemotherapy formulations. Its other product is intratumoral T cell vaccines, which targets epithelial cancers. The company utilizes its proprietary technologies in the development of novel therapeutics for the treatment of antibody-refractory cancers. It also focuses on the discovery and development of programmable immune cell therapies using Autologous Dendritic Cells (DCs) and T cells; Identification of Biotherapeutics for Cancer; Antibody Directed Selection/Activation of T Cells (ADSTAT); and Novel Cancer Therapeutic Products Development Platforms.
Latest events on Quartr
Previous Events for Lyell Immunopharma Inc
Ticker
LYEL
Country
United States of America
About the company
Investor Relations page
Dig deeper into the fundamentals using Quartr - Investor relations
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
